Manifold Bio

Executive Summary

Manifold Bio is a private biotechnology company based in Cambridge, MA, founded in 2019. It has developed a proprietary high-throughput in vivo (HTV) discovery platform that integrates massively multiplexed in vivo screening with AI-driven protein design to generate tissue-targeted biologics. The platform's mCodes technology allows simultaneous tracking and quantification of hundreds of therapeutic candidates in a single animal, dramatically accelerating the drug discovery process. By enabling rapid iteration and selection of optimized biologics, Manifold aims to address previously undruggable targets and improve therapeutic indices. The company's innovative approach positions it at the forefront of next-generation biologic discovery, with potential applications across oncology, immunology, and other therapeutic areas. As a private entity, Manifold Bio has not disclosed specific financial details or clinical-stage programs, but its platform technology has attracted attention for its potential to transform biologics development. Upcoming catalysts for Manifold Bio include the nomination of its first lead development candidate from the platform, which would validate the end-to-end capability of the HTV engine. Additionally, presentation of preclinical in vivo efficacy data at major scientific conferences could demonstrate the platform's power in targeting difficult tissues. Finally, the company may announce a significant financing round, such as a Series B, to fund pipeline expansion and platform advancement. These events are typical for a private biotech of its stage and would mark important milestones in its evolution.

Upcoming Catalysts (preview)

• TBDNomination of first lead development candidate60% success
• TBDPresentation of preclinical in vivo efficacy data at a major conference70% success
• TBDAnnouncement of Series B financing round50% success